Cingulate (CINGW) Accumulated Depreciation (2021 - 2026)
Cingulate's (CINGW) quarterly Accumulated Depreciation came in at $4.1 million in Q2 2026, up 12.42% on a YoY basis from $3.6 million in Q2 2025, and up 5.72% quarter-over-quarter from $3.8 million in Q4 2025.
Analysis
Cingulate (CINGW) Accumulated Depreciation (2021 - 2026) Analysis & Trends
Cingulate (CINGW) has reported Accumulated Depreciation for 6 consecutive years, with $4.1 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Accumulated Depreciation rose 12.42% year-over-year to $4.1 million; the trailing twelve-month figure through Jun 2026 stood at $4.1 million (up 12.42% YoY), and the FY2025 full-year result was $3.8 million, up 16.41% from the prior year.
- Accumulated Depreciation improved to $4.1 million in Q2 2026 per CINGW's latest filing, from $3.8 million in the prior quarter.
- Across five years, Accumulated Depreciation topped out at $4.1 million in Q2 2026 and bottomed at $1.8 million in Q1 2022.
- Historically, Accumulated Depreciation has averaged $2.8 million across 5 years, with a median of $2.8 million in 2024.
- The sharpest annual moves came in 2024 and 2026: Accumulated Depreciation gained 29.89% in 2024, then gained 12.42% in 2026.
- Over 5 years, Accumulated Depreciation stood at $2.1 million in 2022, then increased by 28.3% to $2.6 million in 2023, then gained by 24.71% to $3.3 million in 2024, then gained by 16.41% to $3.8 million in 2025, then climbed by 5.72% to $4.1 million in 2026.
- According to Business Quant data, Accumulated Depreciation over the past three periods registered $4.1 million, $3.8 million, and $3.7 million for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.24 Bn | 625.48 Bn | 17.26 Bn |
| 2 | AbbVie | 441.52 Bn | 434.96 Bn | 12.70 Bn |
| 3 | Merck | 365.75 Bn | 358.60 Bn | 12.21 Bn |
| 4 | Novartis Ag | 266.61 Bn | 258.92 Bn | 11.24 Bn |
| 5 | Pfizer | 159.09 Bn | 147.39 Bn | 10.94 Bn |
| 6 | Sanofi | 52.43 Bn | 45.05 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - |
| 8 | Incyte | 25.32 Bn | 20.79 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.43 Bn | 18.77 Bn | 683.80 Mn |
| 10 | Cingulate | 100,214.03 | 100,214.03 | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 4.06 Mn |
| Dec 31, 2025 | 3.84 Mn |
| Sep 30, 2025 | 3.72 Mn |
| Jun 30, 2025 | 3.61 Mn |
| Mar 31, 2025 | 3.46 Mn |
| Dec 31, 2024 | 3.30 Mn |
| Sep 30, 2024 | 3.14 Mn |
| Jun 30, 2024 | 2.97 Mn |
| Mar 31, 2024 | 2.81 Mn |
| Dec 31, 2023 | 2.64 Mn |
| Sep 30, 2023 | 2.47 Mn |
| Jun 30, 2023 | 2.32 Mn |
| Mar 31, 2023 | 2.16 Mn |
| Dec 31, 2022 | 2.06 Mn |
| Sep 30, 2022 | 1.97 Mn |
| Jun 30, 2022 | 1.87 Mn |
| Mar 31, 2022 | 1.77 Mn |
| Dec 31, 2021 | 1.67 Mn |